Fast turnaround engagement with a top pharma to assess the market potential and opportunity in 7 international markets (China, Korea, Japan, Russia, Brazil and Mexico) and development of revenue forecast for an asset in development for Crohn’s Disease and Ulcerative Colitis to assist with go-/no-go decision for launch in these secondary international markets.
GlobalData supported the client to understand the opportunity for their asset in the two IBD indications and fine tune the revenue projections for 7 international markets, to support the prioritization of geographies as part of its launch strategy planning.
Our Solution
- GlobalData leveraged its proprietary platforms and addressed the gaps from internal data with additional secondary research to give the client a comprehensive overview of the disease landscape specific to each international market of interest to the client.
- GlobalData also leveraged its epidemiological data from syndicated team. These were complemented by 3rd party demand based sales data and triangulated with an in-depth literature search, in order to validate, refine and tailor the data that would feed the revenue model’s inputs. This allowed to generate country-specific revenue forecasts that relied solely on secondary research inputs.
- The core deliverables contained sales forecast (Excel), and a deck (Power Point) assessing competitive landscape and guidelines across the 7 markets.
Outcome
Through creation of dynamic revenue forecasts and peak year projections, GlobalData supported the client’s go-/no-go launch decision for the IBD indications in 7 markets. The project involved a strong component of collaboration between GlobalData and the client’s leadership teams.
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
